Your browser is no longer supported. Please, upgrade your browser.
Settings
PTGX Protagonist Therapeutics, Inc. daily Stock Chart
PTGX [NASD]
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own2.00% Shs Outstand23.62M Perf Week10.88%
Market Cap192.50M Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float22.02M Perf Month15.11%
Income-28.10M PEG- EPS next Q-0.45 Inst Own- Short Float2.36% Perf Quarter-11.03%
Sales39.90M P/S4.82 EPS this Y18.90% Inst Trans1.18% Short Ratio4.75 Perf Half Y2.90%
Book/sh5.41 P/B1.51 EPS next Y-30.90% ROA-18.80% Target Price14.75 Perf Year-57.20%
Cash/sh5.86 P/C1.39 EPS next 5Y- ROE-24.10% 52W Range5.49 - 23.97 Perf YTD21.10%
Dividend- P/FCF- EPS past 5Y- ROI-31.40% 52W High-66.00% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low48.38% ATR0.53
Employees62 Current Ratio6.10 Sales Q/Q-30.70% Oper. Margin-76.10% RSI (14)62.90 Volatility9.47% 7.43%
OptionableNo Debt/Eq0.00 EPS Q/Q-33.60% Profit Margin-70.50% Rel Volume1.55 Prev Close7.96
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 AMC Payout- Avg Volume109.32K Price8.15
Recom1.80 SMA2017.59% SMA5011.94% SMA2001.73% Volume169,878 Change2.39%
Dec-06-18Initiated Nomura Buy $13
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
Jan-16-19 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jan-09-19 07:00AM  Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia PR Newswire
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
Dec-20-18 10:42AM  Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares? Simply Wall St.
Dec-13-18 07:00AM  Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943 PR Newswire
Dec-05-18 07:00AM  Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference PR Newswire
Nov-29-18 08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-27-18 04:01PM  Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease PR Newswire
Nov-09-18 08:40AM  New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-07-18 04:30PM  Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 PR Newswire
Nov-06-18 08:05PM  Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.58%
06:59PM  Protagonist Therapeutics: 3Q Earnings Snapshot Associated Press
04:23PM  Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
07:00AM  Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 PR Newswire
Oct-29-18 10:31AM  Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release Zacks
Oct-22-18 08:31AM  Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week PR Newswire -7.05%
Oct-10-18 07:35AM  Report: Developing Opportunities Within Apollo Investment, Ladder Capital, Medpace, MPLX LP, Silicon Laboratories, and Protagonist Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 07:13AM  Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting PR Newswire
Sep-27-18 07:00AM  Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 PR Newswire +15.32%
Sep-24-18 07:00AM  Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 PR Newswire
Sep-19-18 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Sep-06-18 07:01AM  Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 PR Newswire
07:00AM  Protagonist Therapeutics Expands Intellectual Property Portfolio PR Newswire
Aug-17-18 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Aug-08-18 11:21AM  Protagonist Stock Jumps 58% After Re-Review of Test Results InvestorPlace
Aug-07-18 06:00PM  Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:57PM  Protagonist Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Protagonist Therapeutics Reports Second Quarter 2018 Financial Results PR Newswire
08:00AM  Todays Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Aug-06-18 07:01AM  Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis PR Newswire +58.63%
07:00AM  Protagonist Therapeutics Secures $22 Million Equity Financing PR Newswire
Aug-01-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire
Jun-18-18 07:00AM  Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting PR Newswire
Jun-06-18 07:00AM  Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference PR Newswire
Jun-01-18 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
May-24-18 04:30PM  Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer PR Newswire
May-22-18 07:30AM  Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage Future Expectations, Projections Moving into 2018 GlobeNewswire
May-17-18 10:14AM  Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association PR Newswire -7.13%
May-16-18 08:00AM  Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors PR Newswire
May-09-18 05:16PM  Protagonist Therapeutics: 1Q Earnings Snapshot Associated Press
04:02PM  Protagonist Therapeutics Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 08:00AM  Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference PR Newswire
Apr-13-18 08:18AM  Protagonist Therapeutics (PTGX) Enters Oversold Territory Zacks
Mar-28-18 05:02PM  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion Zacks -6.31%
08:25AM  Recent Analysis Shows ICU Medical, Motorcar Parts of America, Protagonist Therapeutics, A. Schulman, PennantPark Investment, and H&E Equipment Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-27-18 10:08AM  Protagonist Therapeutics Stalls Ulcerative Colitis Study Zacks
Mar-26-18 04:31PM  Why KB Home, Longfin, and Protagonist Therapeutics Slumped Today Motley Fool -57.17%
11:45AM  Why Protagonist Therapeutics, Inc. Is Imploding Today Motley Fool
06:45AM  Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis PR Newswire
Mar-09-18 08:00AM  Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference PR Newswire +14.09%
Mar-08-18 06:26PM  Edited Transcript of PTGX earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-18 04:58PM  Protagonist Therapeutics posts 4Q loss Associated Press
04:02PM  Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results PR Newswire
12:00PM  Protagonist Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:43AM  Analysts Expect Breakeven On The Horizon For Protagonist Therapeutics Inc (NASDAQ:PTGX) Simply Wall St.
Mar-06-18 04:30PM  FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia PR Newswire
Mar-01-18 04:00PM  Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference PR Newswire
07:00AM  Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow PR Newswire
Jan-31-18 08:00AM  Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-29-18 12:14PM  Protagonist Therapeutics 'Poised For Upside,' Stifel Says Benzinga +13.10%
Jan-25-18 07:40AM  Analysis: Positioning to Benefit within AllianceBernstein Holding, Motorcar Parts of America, Aegion, Zix, Workiva, and Protagonist Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-04-18 08:00AM  Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 PR Newswire
Dec-15-17 09:12AM  The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals Zacks
Dec-14-17 06:31AM  Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors PR Newswire
06:30AM  Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire
Dec-04-17 08:00AM  Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire -8.21%
Nov-20-17 07:25AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017 Capital Cube +6.67%
Nov-10-17 01:24PM  Protagonist Therapeutics, Inc. Value Analysis (NASDAQ:PTGX) : November 10, 2017 Capital Cube
Nov-09-17 08:00AM  Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 PR Newswire
07:19AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 9, 2017 Capital Cube
Nov-06-17 04:21PM  Protagonist Therapeutics posts 3Q loss Associated Press
04:01PM  Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Nov-01-17 04:17PM  Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference PR Newswire
Oct-26-17 08:48AM  Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics Zacks
Oct-11-17 10:25PM  Protagonist Therapeutics Prices Public Offering of Common Stock PR Newswire
04:01PM  Protagonist Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Sep-20-17 08:00AM  Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire
Sep-14-17 12:38PM  /C O R R E C T I O N -- Protagonist Therapeutics, Inc./ PR Newswire +5.13%
Sep-11-17 04:01PM  Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Aug-24-17 04:01PM  Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment PR Newswire +9.42%
Aug-08-17 04:16PM  Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights PR Newswire
Jun-08-17 08:00AM  Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors PR Newswire
Jun-07-17 05:01PM  A small biotech wants to disrupt billion-dollar injectable drug markets with a single pill Business Insider
May-31-17 10:40AM  Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News 24/7 Wall St. -5.50%
May-30-17 06:25PM  Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen TheStreet.com +43.80%
09:30AM  Why Protagonist Therapeutics Shares Are Climbing 24/7 Wall St.
07:00AM  Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease PR Newswire
May-25-17 08:00AM  Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 PR Newswire -5.60%
May-24-17 08:00AM  Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity PR Newswire -7.71%
May-10-17 04:46PM  Protagonist Therapeutics posts 1Q loss Associated Press
04:01PM  Protagonist Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
May-04-17 05:23PM  Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200 PR Newswire
Apr-20-17 04:21PM  Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week PR Newswire
Mar-11-17 01:04PM  PROTAGONIST THERAPEUTICS, INC Financials
Mar-09-17 08:00AM  Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference PR Newswire
Mar-07-17 05:44PM  Protagonist Therapeutics posts 4Q loss Associated Press
04:36PM  PROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results PR Newswire
Mar-02-17 08:00AM  Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference PR Newswire
Feb-17-17 06:00AM  Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress PR Newswire
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATEL DINESH V PH DPresident and CEOJan 11Option Exercise1.1622,34425,919368,173Jan 14 07:00 PM
CANAAN X L.P.10% OwnerMay 17Sale6.0938,968237,3582,116,552May 21 04:34 PM
CANAAN X L.P.10% OwnerMay 16Sale6.4629,441190,0712,155,520May 16 05:16 PM
CANAAN X L.P.10% OwnerMay 15Sale6.4857,715374,0802,184,961May 16 05:16 PM
CANAAN X L.P.10% OwnerMay 14Sale6.3777,591494,2242,242,676May 16 05:16 PM
PATEL DINESH V PH DPresident and CEOMay 10Option Exercise1.1613,51615,679265,779May 11 06:50 PM
PATEL DINESH V PH DPresident and CEOApr 02Option Exercise1.1620,00023,200252,263Apr 03 05:17 PM
PATEL DINESH V PH DPresident and CEOMar 26Option Exercise0.8711,2989,829232,263Mar 28 05:20 PM
CANAAN X L.P.10% OwnerMar 23Sale20.7159,9501,241,3252,320,267Mar 26 04:25 PM
CANAAN X L.P.10% OwnerMar 22Sale20.624,75998,1332,380,217Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 21Sale20.6117,699364,7272,384,976Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 20Sale20.6117,060351,5382,402,675Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 19Sale20.5713,439276,4462,419,735Mar 19 05:22 PM
CANAAN X L.P.10% OwnerMar 16Sale20.516,926142,0632,433,174Mar 19 05:22 PM
CANAAN X L.P.10% OwnerMar 15Sale20.6411,751242,5212,440,100Mar 15 04:55 PM
CANAAN X L.P.10% OwnerMar 14Sale20.772004,1542,451,851Mar 15 04:55 PM
CANAAN X L.P.10% OwnerMar 13Sale20.841,20425,0942,452,051Mar 15 04:55 PM
Liu David YChief Scientific OfficerMar 12Option Exercise4.213,50014,73518,528Mar 13 04:48 PM
Liu David YChief Scientific OfficerMar 12Sale21.293,50074,50015,028Mar 13 04:48 PM
Liu David YChief Scientific OfficerMar 02Option Exercise1.898751,65414,197Mar 02 07:17 PM
Liu David YChief Scientific OfficerMar 02Sale20.0087517,50013,322Mar 02 07:17 PM